Zentalis Pharmaceuticals Inc (ZNTL) Hedge Fund & Institutional Holdings (Q2 2026)

ZNTL ranks #4261 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

ZNTL is a disclosed holding of Two Sigma (Two Sigma Investments), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

ZNTL is a top-conviction position for 5AM Venture Management, LLC — at 6.7% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in ZNTL belongs to Squadron Capital Management LLC, but the position matters far more to 5AM Venture Management, LLC, who has 6.7% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

BlackRock has added to its ZNTL position for two straight quarters, increasing it by $16.5M to reach $18.2M today.

JPMorgan has trimmed its ZNTL position for two straight quarters, cutting it by $146.3K while still holding $103.4K.

ZNTL is down 2.1% today, but institutions show net buying of $29.3M this quarter — a divergence between today's price move and the underlying institutional flow.

ZNTL reported a net loss of $139.5M over the trailing twelve months.

• Not yet profitable — net loss of $139.5M over the trailing twelve months
• Revenue declined 100.0% year over year
• Net income improved year over year, from -$162.8M to -$139.5M
• Operating cash flow was negative, using $125.2M in cash
• Current ratio of 6.93x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.34x equity — within a conventional range